Effect of COVID-19 Vaccination on Thyroid Disease in 7 Million Adult and 0.2 Million Adolescent Vaccine Recipients

초록

BACKGROUND: Emerging reports have raised concerns regarding the potential link between COVID-19 vaccination and thyroid dysfunction, specifically thyroiditis. OBJECTIVE: This study aimed to investigate the potential association between COVID-19 vaccination and the prevalence of thyroid diseases using data from a Korean national cohort. METHODS: This study included 7,579,210 adult and 241,063 adolescent vaccine recipients. A self-controlled case series design was applied to estimate the incidence rate ratio (IRR) of thyroid disease during the 55-day post-vaccination period (first and second dose) compared to the baseline period (non-exposure period) using conditional Poisson regression. RESULTS: In the adult population, IRRs for hyperthyroidism, hypothyroidism, subacute thyroiditis, and thyroid eye disease were 0.98 (95% CI 0.89-1.09), 0.91 (95% CI 0.84-0.98), 1.27 (95% CI 0.94-1.72), and 0.68 (95% CI 0.50-0.93) after the first vaccine dose and 0.96 (95% CI 0.87-1.06), 0.93 (95% CI 0.87-0.99), 1.32 (95% CI 0.96-1.80), and 1.06 (95% CI 0.81-1.38) after the second vaccine dose. While the risk of hyperthyroidism recurrence did not increase after vaccination, we observed an increased risk of hypothyroidism exacerbation. Subgroup analyses based on age, sex, and vaccine type revealed no significant differences in the incidence of thyroid diseases. In adolescents aged 12-17 years, no increase in the risk of thyroid disease was observed after vaccination. CONCLUSIONS: This extensive national self-controlled case series analysis found an increased risk of exacerbation of hypothyroidism following COVID-19 vaccination. However, no significant association was observed between COVID-19 vaccination and an increased risk of most other thyroid diseases. These findings contribute to increasing evidence supporting the safety of COVID-19 vaccination in relation to thyroid health. © The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com. See the journal About page for additional terms.

키워드